Impetigo Clinical Trial
Official title:
A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo.
This study aims to investigate the efficacy and safety of topical p-menthane-3,8-diol (PMD)-rich Corymbia Citriodora oil (Citriodiol®) in children with impetigo. Citriodiol® is already known to be effective as an insect repellent and is safe in its topical application. The investigators have also found in our laboratory that it is bactericidal against Staphylococcus aureus, the bacteria responsible for causing impetigo. Parents are always searching for a natural alternative to antibiotics (the current gold standard treatment for impetigo), and the investigators believe Citriodiol® could provide this possible alternative.
The extract of lemon eucalyptus, a common plant, has since the 1970s been used in commercial
insect repellent products. Recently, it has been shown that lemon eucalyptus has potent
anti-bacterial and anti-fungal effects that should assist in the treatment of inflammatory
conditions such as impetigo. Our aim is to investigate this further by investigating the
safety and efficacy of this product in the treatment of Impetigo.
A randomised, double-blinded, three-armed pilot study, involving a total of 30 patients will
be recruited from the dermatology outpatient department clinic at Royal North Shore hospital
for this study. These patients will be between the ages of 12 months and 12 years with a
clinical diagnosis of Impetigo.
The three treatment groups will include a 2% or 5% topical p-menthane-3,8-diol (extracted
from lemon eucalyptus) and a topical Mupirocin arm, which will be applied topically twice a
day till resolution of symptoms. Follow-up will occur weekly until resolution of symptoms,
which is expected within 2 weeks. Photographs, disease severity assessment and lesional
swabs for culture will be taken at recruitment and as progress.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00884728 -
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory
|
N/A | |
| Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
| Completed |
NCT01153828 -
EU PV for Retapamulin-Prescribing
|
N/A | |
| Recruiting |
NCT05345093 -
Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, Impetigo and Folliculitis
|
N/A | |
| Active, not recruiting |
NCT05226260 -
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
|
N/A | |
| Terminated |
NCT00986856 -
Fucidin® Cream in the Treatment of Impetigo
|
Phase 4 | |
| Completed |
NCT01397461 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
| Recruiting |
NCT02090764 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
| Completed |
NCT02775617 -
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
|
Phase 4 | |
| Completed |
NCT03177993 -
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
|
N/A | |
| Completed |
NCT03429595 -
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
|
Phase 2 | |
| Completed |
NCT04287777 -
Safety and Efficacy of Mupirocin Gel in Children With Impetigo
|
Phase 3 | |
| Completed |
NCT00626795 -
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
|
Phase 2 | |
| Completed |
NCT00758862 -
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
|
Phase 2 | |
| Recruiting |
NCT01943136 -
The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial
|
Phase 1 | |
| Completed |
NCT01670032 -
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
|
Phase 2/Phase 3 | |
| Completed |
NCT01171326 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
|
Phase 2 | |
| Completed |
NCT01367314 -
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
|
Phase 2 | |
| Completed |
NCT01126268 -
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
|
Phase 4 | |
| Completed |
NCT00852540 -
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
|
Phase 3 |